Business Context and Reporting Period
This Form 8-K is filed by Coeptis Therapeutics Holdings, Inc. (not Z Squared Inc.) on July 30, 2024. The report addresses a critical corporate governance event regarding the company's continued listing status on the Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, or debt. However, it discloses a material financial threshold failure:
- Stockholders' Equity: The company failed to meet the minimum stockholders' equity initial listing requirement of $5,000,000 under Nasdaq Listing Rule 5505(b).
- Stock Price: The company failed to maintain the minimum bid price of $1.00 per share for 30 consecutive business days.
Material Changes and Events
The primary material change is the receipt of a Delisting Determination Letter from Nasdaq on July 30, 2024. Key details include:
- Non-Compliance: The company did not regain compliance with the Minimum Bid Price Requirement by the July 29, 2024 deadline.
- Extension Denial: The company was denied a second 180-day compliance extension because it did not meet the $5,000,000 stockholders' equity requirement.
- Consequence: Unless a hearing is requested, trading of the Common Stock (COEP) and Warrants (COEPW) is scheduled to be suspended on August 8, 2024, followed by delisting.
Outlook, Management Commentary, and Risks
Management intends to request a hearing before a Nasdaq Hearing Panel by August 6, 2024 to appeal the delisting determination. The company expects this request to stay the suspension of trading pending the hearing's conclusion.
- Proposed Remedy: The company plans to present a compliance plan to the Panel, which may include implementing a reverse stock split, subject to Board and stockholder approval.
- Risks: There is no assurance that the company will regain compliance, successfully implement a reverse stock split, or that the Panel will grant a suspension of delisting. The filing explicitly warns that actual results may differ materially from forward-looking statements.
Investor Verification Checklist
- Verify the filing date of the hearing request with Nasdaq (deadline: August 6, 2024).
- Confirm whether the Board of Directors has approved a reverse stock split plan.
- Monitor the Nasdaq Hearing Panel's decision regarding the suspension of delisting.
- Review the company's most recent Form 10-K for detailed "Risk Factors" and current stockholders' equity figures.
- Check for any subsequent trading suspensions on the Nasdaq Capital Market.